| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020343 | HARM REDUCTION THERP | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(8 years from now) | |
| US11806428 | HARM REDUCTION THERP | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(8 years from now) | |
Rivive is owned by Harm Reduction Therp.
Rivive contains Naloxone Hydrochloride.
Rivive has a total of 2 drug patents out of which 0 drug patents have expired.
Rivive was authorised for market use on 28 July, 2023.
Rivive is available in spray, metered;nasal dosage forms.
Rivive can be used as use of intranasal naloxone for the treatment of opioid overdose.
The generics of Rivive are possible to be released after 11 May, 2032.
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2023
Treatment: Use of intranasal naloxone for the treatment of opioid overdose
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
RIVIVE family patents
